ArticleThe British journal of ophthalmology2025
Timing of nodal metastasis in patients with eyelid sebaceous carcinoma and implications for surveillance and survival.
Article in The British journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
aimsSebaceous carcinoma (SC) is a rare cancer with periocular predilection. Studies focused on patterns and timing of nodal metastasis are scarce.Our aim is to report patterns of regional nodal metastasis in patients with eyelid SC, including results of sentinel lymph node biopsy (SLNB).
methodsAll consecutive patients with eyelid SC treated during 1999-2023 were retrospectively reviewed.All subjects had standard of care surgery for eyelid SC and regional lymph node evaluation using physical examination and ultrasonography (US) at baseline and during the surveillance period. 38 patients with negative findings on US had SLNB to rule out microscopic metastasis.The frequency and timing of lymph node metastasis, the SLNB positivity rate, management of nodal metastasis, overall and disease-specific survival were analysed.
resultsA total of 138 patients were included. 30 patients (22%) had lymph node metastasis: 15 patients were diagnosed at the time of initial diagnosis of eyelid SC; 18 patients developed nodal metastasis during the follow-up period, at a median of 12 months (range, 1-132). Of 38 patients, 5 (13%) had a positive SLNB. Management of nodal metastasis entailed surgical resection of the involved nodal basins in 27 patients; 20 had adjuvant radiotherapy and 7 had adjuvant concurrent chemoradiation. In patients with nodal metastasis, the 2-year and 5-year disease-specific survival rates were 87.5% and 75.4%, respectively.
conclusionsOne-half of the patients with eyelid SC with nodal metastasis had negative findings at initial presentation but developed nodal metastasis during follow-up, highlighting the importance of continued lymph node surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.